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SUMMARY Rest-activity rhythm disruption is a prominent clinical feature of Alzheimer’s disease
(AD). The origin of the altered rest-activity rhythm is believed to be degeneration of the
suprachiasmatic nucleus (SCN). In accordance with the use it or lose it hypothesis of
Swaab [Neurobiol Aging 1991, 12: 317–324] stimulation of the SCN may prevent age-
related loss of neurons and might reactivate nerve cells that are inactive but not lost.
Previous studies with relatively small sample sizes have demonstrated positive eﬀects of
peripheral electrical nerve stimulation on the rest-activity rhythm in AD patients. The
present randomized, placebo-controlled, parallel-group study was meant to replicate
prior ﬁndings of electrical stimulation in AD in a substantially larger group of AD
patients. The experimental group (n ¼ 31) received peripheral electrical nerve stimu-
lation and the placebo group (n ¼ 31) received sham stimulation. Eﬀects of the
intervention on the rest-activity rhythm were assessed by using wrist-worn actigraphs.
Near-signiﬁcant ﬁndings on the rest-activity rhythm partially support the hypothesis
that neuronal stimulation enhances the rest-activity rhythm in AD patients. Interest-
ingly, post-hoc analyses revealed signiﬁcant treatment eﬀects in a group of patients who
were not using acetylcholinesterase inhibitors concomitantly. We conclude that more
research is needed before ﬁrm general conclusions about the eﬀectiveness of electrical
stimulation as a symptomatic treatment in AD can be drawn. In addition, the present
post-hoc ﬁndings indicate that future studies on non-pharmacological interventions
should take medication use into account.
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INTRODUCTION
Disruption of the daily rest-activity rhythm is a prominent
clinical feature of Alzheimer’s disease (AD) (Ancoli-Israel
et al., 1997; McCurry et al., 1999; Paavilainen et al., 2005;
Satlin et al., 1995; Van Someren et al., 1996). In a large study,
the prevalence of symptoms of disordered sleep in AD ranged
from 34% (waking up at night thinking it is daytime) to 82%
(getting up during the night) (Tractenberg et al., 2003).
Moreover, a recent study reported signiﬁcantly more subject-
ive sleep disturbances in AD patients when compared with
non-demented elderly patients, and in addition, greater sleep
disturbance appeared to be associated with greater functional
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impairment (Tractenberg et al., 2005). Therefore, it is not
surprising that institutionalization is best predicted by rest-
activity rhythm disruption and not by the level of cognitive
functioning or by the number of psychiatric symptoms of the
AD patient (Chenier, 1997; Hart et al., 2003; Hope et al.,
1998; Kesselring et al., 2001; Lieberman and Kramer, 1991;
Pollak and Perlick, 1991).
The origin of the altered rest-activity rhythm in AD is
believed to be a degeneration of the suprachiasmatic nucleus
(SCN) (Liu et al., 2000; Swaab et al., 1996), which is part of
the hypothalamus and considered the biological clock of the
brain (Inouye and Shibata, 1994). Higher daytime light
exposure seems to have a positive impact on night-time sleep
consolidation in both demented and non-demented elderly
patients (Shochat et al., 2000). Interestingly, application of
bright light has been shown to positively inﬂuence rest-activity
rhythm disturbances in some AD patients (Fetveit and
Bjorvatn, 2004; Fetveit et al., 2003; Koyama et al., 1999;
Lyketsos et al., 1999; Satlin et al., 1992; Van Someren et al.,
1997; Yamadera et al., 2000). One explanation for this
therapeutic action is that light stimulates the SCN through a
central pathway, i.e. the retino-hypothalamic nerve tract, and
prevents age-related loss of neurons in this nucleus (Van
Someren et al., 1997). The latter has been found in animal
experiments (Lucassen et al., 1995) and is in line with the use
it or lose it hypothesis which states that an organism proﬁts
from neuronal stimulation (Swaab, 1991).
The biological clock may also be stimulated through
pathways originating in the peripheral nervous system. An
intervention aimed at stimulating peripheral nerves is applica-
tion of electrical stimuli to the skin. Two placebo-controlled
studies have demonstrated positive eﬀects of transcutaneous
electrical nerve stimulation (TENS) on the rest-activity rhythm
in institutionalized AD patients in terms of improved stability
(Scherder et al., 1999; Van Someren et al., 1998). It was argued
that stimulation of peripheral nerves with electrical stimuli
might activate the SCN through four projections that were
identiﬁed in animal experimental studies. First, the spino-
hypothalamic tract: a direct pathway from the spinal cord to
the SCN (Cliﬀer et al., 1991). Second, a spino-septal-hypotha-
lamic tract: an indirect pathway from the spinal cord to the
septal nuclei (Burstein and Giesler, 1989), and subsequently to
the SCN (Pickard, 1982). Third and fourth are spino-brain-
stem-hypothalamic tracts: from the spinal cord to the brain
stem locus coeruleus (LC) (Kawano et al., 1996) and further to
the SCN (Krout et al., 2002) and from spinal cord to the raphe
nuclei (Hay-Schmidt et al., 2003; Kawano et al., 1996) and
subsequently to the SCN (Krout et al., 2002; Moga and
Moore, 1997).
In addition, the LC and the raphe nuclei are known to
innervate the basal forebrain (Jones, 2003). From the basal
forebrain, including the nucleus basalis of Meynert, cholinergic
cells project to the cerebral cortex (Jones, 2004) and to the
SCN (Yamadera et al., 2000). The noradrenergic LC and
serotonergic raphe nuclei are parts of the ascending reticular
activating system (Kayama and Koyama, 1998), which is
known to play an important role in the regulation of sleep and
wakefulness (Siegel, 2004). Hence, assuming homologous
pathways exist in these animals and humans, stimulation of
peripheral nerves could account for the eﬀects of electrical
stimulation previously found in AD patients. These positive
results of electrical stimulation in AD were based on samples
of 14 and 16 patients (Scherder et al., 1999; Van Someren
et al., 1998) and should therefore be interpreted with caution.
The present, randomized, placebo-controlled, parallel-group
clinical study, was an attempt to replicate previous ﬁndings of
electrical stimulation in AD in a larger number of patients.
Based on the earlier studies, it was hypothesized that after a
treatment period of 6 weeks, the experimental group, which
received electrical stimulation, would show improved func-
tioning of the rest-activity rhythm compared with the placebo
group, which received sham stimulation.
METHODS
Subjects
Participants were recruited from the Alzheimer Center of the
VU University Medical Center, from the Department of
Neurology, Sint Lucas Andreas Hospital, and from the
community home care agency in Amsterdam, the Netherlands.
Both men and women were eligible if they met the diagnostic
criteria of the NINCDS/ADRDA for probable AD
(McKhann et al., 1984). A Mini Mental State Examination
(MMSE) (Folstein et al., 1975) score of 26 or lower and
suﬃcient hearing and vision were required. It was essential that
the AD patient was living at home with a partner or other
family member who served as primary caregiver. Concomitant
use of acetylcholinesterase inhibitors (AChEIs) for sympto-
matic treatment of AD was allowed only if the dose was stable
before the ﬁrst assessment and remained unchanged during the
trial. Patients with a diagnosis of dementia other than AD,
cerebrovascular disease or clinical depression were excluded, as
were patients who had a history of cerebral trauma, distur-
bances of consciousness, seizures, epilepsy, or an infectious
disease. Patients with a cardiac pacemaker were excluded
because of reported interference between a pacemaker and an
electrical stimulator (Rasmussen et al., 1988).
After the procedure of the study had been fully explained,
written informed consent was obtained from the patient and/
or the family caregiver. The study was approved by the local
medical ethics committees and by the Committee on Research
Involving Human Subjects in The Hague, the Netherlands.
Sixty-eight patients were included and randomly allocated to
either an experimental group that received electrical stimula-
tion or to a placebo group that received sham stimulation.
Sixty-ﬁve patients (96%) completed the study. Discontinuation
during the treatment phase occurred only in the placebo group
and was due to refused treatment (n ¼ 1), stroke (n ¼ 1), and
a partner who sustained an arm fracture (n ¼ 1). Three
additional cases were excluded from analysis because no
actigraph data were available. Finally, 62 patients (91%)
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entered the analysis phase. The two groups did not diﬀer
signiﬁcantly with regard to sex, age, education, and MMSE as
indicated by chi-squared and t-tests (see Table 1 for group
characteristics).
In view of the hypothesized involvement of the cholinergic
system in the mechanism underlying the eﬀects of electrical
stimulation in AD and the use of AChEIs in a part of the
sample, we explored the possible interaction between AChEIs
and electrical stimulation. The experimental and placebo
group were both split into AChEI users (AChEI +) and
AChEI non-users (AChEI )), resulting in four groups:
experimental AChEI ) (n ¼ 16), experimental AC-
hEI + (n ¼ 15), placebo AChEI ) (n ¼ 18), and placebo
AChEI + (n ¼ 13). Post-hoc multiple analyses of variance
(manova) and chi-squared tests indicated no signiﬁcant diﬀer-
ences between the groups with respect to age, education,
MMSE, and sex.
Randomization and blinding
Using simple randomization by tossing a coin, the participants
were allocated to the experimental or placebo group. Those
assigned to the experimental group were given the real
treatment, i.e. electrical stimuli applied to the skin (see
Intervention section below for more details) whereas partici-
pants in the placebo group were told that the stimulator was
working as soon as a green light was blinking, without actual
current being applied. To maintain the participants blindness
and as the participants knew there was an experimental and a
placebo condition, the two groups were informed as follows.
The experimental group was told that diﬀerent pulse frequen-
cies were applied to both groups: one frequency that may have
the desired eﬀect and one that, on theoretical grounds, was
unlikely be eﬀective. Hence, patients who received the experi-
mental treatment, i.e. the patient felt the stimulus and the
caregiver observed muscle contraction, would still be under the
assumption that they might be treated with non-eﬀective
stimuli. The participants in the placebo group were also told
that diﬀerent pulse frequencies were applied in two groups, but
that the pulse frequencies were in a range that could not be
perceived. Patients, family caregivers, and test administrators
were blinded to group allocation. After the treatment period
and ﬁnal assessment, group assignment was disclosed to all
participants and the individuals of the placebo group were
oﬀered to undergo the experimental treatment as well.
Study design
In this 12-week, randomized, placebo-controlled, parallel-
group study, assessment of the rest-activity rhythm by means
of actigraphy took place at baseline (Pre-assessment), after the
treatment period of 6 weeks (post-assessment) and following a
treatment-free period of 6 weeks (delayed assessment).
Intervention
A standard TENS device and two self-adhesive medical
electrodes (type: Premier 10s and Xytrode, respectively;
Xytron Medical, Apeldoorn, the Netherlands) were used.
The electrodes were placed on the back at the ﬁrst thoracic
vertebra, lateral to the spine. The electrical stimulator
produced biphasic square pulses with a width of 100 ls,
applied in bursts of nine pulses with a frequency of 160 Hz and
a repetition rate of 2 Hz. The intensity of the stimuli was set at
a level that produced painless, visible muscular twitches. These
stimulation parameters were chosen to target aﬀerent nerve
ﬁbers which convey the pulses to cortical and sub-cortical
areas (Scherder et al., 1995, 2003). The family caregiver
applied the treatment 30 min a day, 7 days a week, for a
period of 6 weeks. The patient and family caregiver were free
to decide what time of the day they administered the treatment
in order to minimize interference in the daily routine of the
participants.
Assessment of rest-activity rhythm
Actigraphy is considered a valid measure of rest-activity
rhythms (Ancoli-Israel et al., 2003) and has been successfully
used in healthy elderly and demented elderly patients (Harper
et al., 2004; Van Someren et al., 1996). Traditionally, actigra-
phy has been recorded from the non-dominant wrist but
studies that investigated diﬀerent placement locations found
no diﬀerences between the dominant wrist, non-dominant-
wrist, ankle, or trunk (Jean-Louis et al., 1997; Sadeh et al.,
1994) or favored the dominant wrist when assessment of
optimal variability of motor movement was of interest
(Middelkoop et al., 1997). Therefore, an actiwatch (Cam-
bridge Neurotechnology Ltd, Cambridge, UK) was worn on
the dominant wrist. The small (3 · 4 · 1 cm) and light-weight
actigraph made home recordings of circadian rhythm possible
during several days and caused minimal burden to the
participant. The participants were asked to wear the actigraph
Table 1 Characteristics of the patients
Experimental
group (n ¼ 31)
Placebo
group (n ¼ 31)
No. males/females 16/15 22/9
Age, years
Mean (SD) 71.5 (8.6) 72.8 (8.3)
Range 52–89 55–87
Education, years
Mean (SD) 10.5 (3.9) 10.7 (3.3)
Range 6–20 6–20
MMSE
Mean (SD) 15.7 (6.9) 14.8 (7.1)
Range 0–26 1–26
AChEI use
Rivastigmine (n) 13 12
Donepezil (n) 2 1
AChEI use, acetylcholinesterase inhibitor use, subdivided in Rivastig-
mine (Exelon) and Donepezil (Aricept). SD, standard deviation;
MMSE, Mini Mental State Examination; AChEI, acetylcholinesterase
inhibitor.
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for 7 days. A rather large number of participants provided a
maximum of 4 days of rest-activity rhythm data. Based on the
minimum of 3 days recommended by the American Associ-
ation of Sleep Medicine Consensus report on the use of
actigraphy (Littner et al., 2003) and based on the fact that
group diﬀerences and treatment eﬀects have previously been
reported using only 3 days of actigraphy (see for example:
Harper et al., 2001; Mormont et al., 2000), we chose to
analyze four consecutive days (M ¼ 96 h, SD ¼ 2, range: 72–
96).
The following nonparametric variables were computed and
are described in more detail elsewhere (Witting et al., 1990).
First, interdaily stability (IS) is a measure of the strength of
coupling of the rest-activity rhythm to Zeitgebers (environ-
mental time-cues). High values represent a stable rhythm and
are considered positive. Second, intradaily variability (IV)
serves as a measure of fragmentation of the rhythm. A normal
rest-activity pattern will show one major active period (day)
and one major resting period (night) and thus a low IV,
whereas a fragmented rhythm will show many transitions
between rest and activity during the 24-h cycle and high IV
values. Third, the relative amplitude (RA) is a normalized
variable based on the most active period in the 24-h cycle in
relation to the least active period. A normal pattern will
display a large diﬀerence between daytime activity and nightly
rest. Thus, a high RA is considered positive.
Statistical analysis
Missing data
Two values (<1%) were missing from 62 participants at three
assessments because of noncompliance, i.e. the patient did not
wear the actigraph long enough to compute rest-activity
rhythm variables. Twenty-one values (11%) were missing due
to technical failure of actigraphs. Patterns of missing data were
analyzed per treatment group to evaluate whether data were
Missing Completely at Random (MCAR) (Little and Rubin,
2002). Little’s MCAR tests suggested that data were MCAR
for all three dependent variables [chi-squares with 6 degrees of
freedom ranged from 4.49 (P ¼ 0.61) to 11.50 (P ¼ 0.12)].
Missing values on dependent variables IS, IV, and RA were
imputed using the expectation maximization (EM) method
(Dempster et al., 1977) available in the SPSS software. The
EM method allowed for analysis of the entire sample of 62
participants.
Analyses of eﬀects of electrical stimulation
Paired samples t-tests indicated no diﬀerences between the pre-
assessment (baseline before treatment) and the Delayed-
assessment (after a washout period of 6 weeks) on any of the
dependent variables, justifying pooling of data from these two
assessments (Kirk, 1995). This procedure resulted in reduced
variability and increased statistical power. The two assess-
ments combined are further referred to as pooled baseline
assessment. To evaluate the eﬀects of the treatment, repeated
measures analyses of variance (anova) with group (two levels:
experimental versus placebo) as between-subjects factor and
time (two levels: pooled baseline versus post) as within
subjects factor were conducted. When interactions
between group and time occurred, within group t-tests were
conducted.
Analyses of interactions between electrical stimulation and
AChEI use
Post-hoc analyses of possible interaction eﬀects between
electrical stimulation and AChEI use were performed. The
experimental and placebo group separately were subject to
repeated measures anova with AChEI use (two levels: AC-
hEI + versus AChEI )) as between-subjects factor and time
(two levels: pooled baseline versus post) as within-subjects
factor. All statistical tests were two-tailed and the critical value
for signiﬁcance was P < 0.01 to compensate for the use of
multiple tests. SPSS Base software for Windows Version 11.5
was used for all statistical analyses.
RESULTS
The experimental group and the placebo group did not diﬀer
on the actigraphy variables IS, IV, or RA at baseline as
indicated by independent samples t-tests. Overall IS before
treatment was 0.60 ± 0.015 (mean ± SEM), IV was
1.07 ± 0.037 and RA was 0.85 ± 0.013. These values are
comparable to previous values found in AD patients and
indicative of a less stable and more fragmented rest-activity
rhythm compared with non-demented elderly patients (Harper
et al., 2004; Scherder et al., 1999; Van Someren et al., 1998).
Eﬀects of electrical stimulation
Repeated-measures anova with group (two levels: experimental
versus placebo) as between-subjects factor and time (two
levels: post versus pooled baseline) as within-subjects factor
revealed a signiﬁcant group · time interaction eﬀect for RA
(F(2,60) ¼ 13.76, P < 0.001) and near-signiﬁcant eﬀects for
IS (F(2,60) ¼ 5.90, P ¼ 0.02) and IV (F(2,60) ¼ 4.24,
P < 0.04). Further analyses using within-group t-tests re-
vealed a trend for improved IS and IV in the experimental
group (t(30) ¼ 1.85, P ¼ 0.07 and t(30) ¼ )1.98, P ¼ 0.06,
respectively) and a signiﬁcant worsening of RA in the placebo
group (t(30) ¼ )3.35, P ¼ 0.002). Note that the decrement of
RA after the treatment period in the placebo group was
temporary and that there was no signiﬁcant diﬀerence between
the assessment before the treatment and after the washout
period of 6 weeks (Table 2).
Interactions between electrical stimulation and AChEI use
To investigate a possible interaction eﬀect between AChEIs
and electrical stimulation, the experimental and placebo group
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separately were subject to repeated-measures anova with
AChEI use (two levels: AChEI + versus AChEI )) as
between-subjects factor and time (two levels: post versus
pooled baseline) as within-subjects factor. The experimental
group revealed a near-signiﬁcant AChEI · time interaction
eﬀect for IS (F(2,29) ¼ 5.00, P ¼ 0.03), whereas the placebo
group showed no signiﬁcant interaction. The eﬀect size in the
experimental group was large, i.e. g2 (Cohen, 1977) was 0.15,
which means that 15% of the variance of treatment outcome in
the experimental group could be attributed to AChEI use, with
better outcome for the group not using an AChEI. Further-
more, within-group t-tests revealed a signiﬁcant eﬀect of the
experimental treatment on IS (t(15) ¼ 3.12, P ¼ 0.007) and a
near-signiﬁcant eﬀect on IV (t(15) ¼ )2.53, P ¼ 0.02) in the
AChEI ) group, but no signiﬁcant eﬀects in the AChEI +
group (t(17) ¼ )0.87, P ¼ 0.40 and t(17) ¼ 1.60, P ¼ 0.13,
respectively) (see Fig. 1). All individual changes in IS within
the experimental and placebo group are shown in Fig. 2. To
further illustrate the above-mentioned ﬁndings on IS and IV,
Fig. 3 shows normalized rest-activity data of a single case that
showed improvement.
DISCUSSION
This paper presents data from a randomized clinical trial on
peripheral electrical nerve stimulation in AD with at least three
times as many participants as any earlier study on this topic to
date. The previous studies (Scherder et al., 1999; Van Someren
et al., 1998) were performed in a nursing home setting and the
treatment in those studies was applied by a professional
trained therapist. In the present study the participants still
lived at home and the treatment was applied by an informal
caregiver, mostly the partner of the patient. Eﬀects of
peripheral electrical stimulation, compared with placebo, on
the rest-activity rhythm in AD patients living at home were
examined. Results indicated near-signiﬁcant group eﬀects on
the stability (IS) and fragmentation (IV) of the rhythm and a
signiﬁcant group eﬀect on the amplitude of the rhythm (RA).
The latter could be attributed to a temporary signiﬁcant
worsening in the placebo group, not to improvement in the
experimental group.
The temporary worsening of RA in the placebo group is a
peculiar ﬁnding and we can only speculate about origins of this
result. One possible explanation is that the temporary
worsening was caused by the so-called nocebo reaction, i.e.
the opposite of the placebo reaction (Benedetti et al., 1997;
Kennedy, 1961). Perhaps the treatment procedure with appli-
cation of electrodes and the use of an electrical apparatus had
a negative connotation to the participants which caused a
negative eﬀect. This nocebo response may have been counter-
balanced in the experimental group by the positive inﬂuence of
the real treatment. We also report a temporary worsening of
the same type of treatment in a diﬀerent group of subjects in
another paper by our group (Luijpen et al., 2004) which points
in the direction of a true eﬀect rather than unreliable data.
The positive results on IS and IV point in the direction of
eﬀects found in earlier studies which showed a more stable
rest-activity rhythm after treatment (Scherder et al., 1999; Van
Someren et al., 1998) and a trend toward a positive eﬀect on
the fragmentation of the rhythm (Scherder et al., 1999).
Table 2 Mean and SEM of the actigraph variables in the experimental and in the placebo group
Experimental group (n ¼ 31), mean ± SEM Placebo group (n ¼ 31), mean ± SEM
Pooled baseline
vs. post statistics
Pre Post Delayed Pre Post Delayed P g2
IS 0.58 ± 0.023 0.60 ± 0.020 0.58 ± 0.018 0.61 ± 0.020 0.57 ± 0.023 0.60 ± 0.022 0.018 0.09
IV 1.02 ± 0.049 0.98 ± 0.055 1.11 ± 0.051 1.11 ± 0.055 1.08 ± 0.055 0.96 ± 0.056 0.044 0.07
RA 0.86 ± 0.015 0.86 ± 0.017 0.85 ± 0.018 0.84 ± 0.022 0.79 ± 0.027 0.86 ± 0.019 0.001 0.19
IS, interdaily stability; IV, intradaily variability; RA, relative amplitude; Pre, baseline; Post, after 6 weeks treatment; delayed, after 6 weeks
treatment-free; pooled baseline, pre and delayed pooled; SEM, standard error of the mean; g2, partial eta squared effect size.
Figure 1. Mean values for interdaily stability
of the experimental (left panel) and placebo
(right panel) group at pooled baseline and
after treatment. There are separate lines for
acetylcholinesterase inhibitor users (AChEI
users) and non-users (AChEI non-users).
Error bars indicate standard errors of the
mean (SEM), shown only one sided for
reasons of clarity.
Eﬀects of electrical nerve stimulation in AD 419
 2006 European Sleep Research Society, J. Sleep Res., 15, 415–423
Therefore, we believe that the near-signiﬁcant ﬁndings on the
rest-activity rhythm, in part, support the hypothesis that
neuronal stimulation enhances the rest-activity rhythm in AD
patients.
Interestingly, the present sample permitted studying the
interaction between electrical stimulation and AChEI intake as
half of the participants were using AChEIs during the trial.
Post-hoc analyses indicated that 15% of the variance of
treatment outcome on IS in the experimental group could be
attributed to AChEI use, with better outcome for the group
not using AChEIs. In addition, the part of the experimental
group not using AChEIs displayed a signiﬁcant within-group
treatment eﬀect for stability of the rhythm and a near-
signiﬁcant eﬀect for fragmentation, whereas the part of the
experimental group also using AChEIs displayed no eﬀects of
electrical stimulation at all.
The ﬁnding that eﬀects were most pronounced in the
subgroup that was not using AChEIs gives food for thought.
Figure 2. Individual changes of interdaily
stability in the experimental group (left panel)
and placebo group (right panel) at pooled
baseline and after treatment. Note in the left
panel the improvement in most of the ace-
tylcholinesterase inhibitor non-users (AChEI
non-users, black lines) in comparison with the
variable changes in the acetylcholinesterase
inhibitor users (AChEI users, gray lines).
Figure 3. Activity proﬁle (4 days of normal-
ized hourly data) of an Alzheimer’s disease
patient before (upper graph) and after treat-
ment (lower graph). This participant was
assigned to the experimental group and was
not using an acetylcholinesterase inhibitor
(AChEI) concomitantly. Note the decreased
fragmentation (i.e., less alternating periods
of high and low activity) and more stability
between days after treatment.
420 K. R. A. Van Dijk et al.
 2006 European Sleep Research Society, J. Sleep Res., 15, 415–423
First, AChEIs are aimed at improving cholinergic function
(Scarpini et al., 2003) and electrical stimulation, among others,
was hypothesized to enhance acetylcholine concentration in
the brain. Concentration–eﬀect curves are often asymmetric-
ally shaped like an inverted U curve (Giraldo et al., 2002) and
therefore it is possible that the subgroup using AChEIs
beneﬁted optimally from the pharmacological treatment, and
electrical stimulation did not have an additional eﬀect. Of
course, this is merely speculation and future research using
positron emission tomography to measure cholinergic function
is necessary. Secondly, if indeed patients that are not using
AChEIs beneﬁt from electrical stimulation, this treatment may
be of importance for those patients who do not tolerate
AChEIs due to side eﬀects like nausea, vomiting, diarrhea, and
anorexia (Birks and Harvey, 2003; Birks et al., 2000; Loy and
Schneider, 2004). Perhaps for those patients an improved rest-
activity rhythm may positively inﬂuence cognitive and/or
behavioral symptoms after long-term treatment periods, a
relation that has been suggested in several studies (Bonanni
et al., 2005; Van Someren et al., 2002). Finally, it is important
to acknowledge that, although we did not ﬁnd any diﬀerences
between the AChEI users and AChEI non-users on any
demographic variable, eﬀects of electrical stimulation in the
subgroup not formed by experimental allocation (in this case
AChEI non-users) may be the result of selection bias prior to
entering the study and should therefore be conﬁrmed in future
experiments.
An interesting issue is whether the near-signiﬁcant eﬀects on
the rhythm have any clinical relevance. On one hand, data
about behavioral outcomes in the participants from the present
study showed no signiﬁcant eﬀects on subjective self-report
and informant-based questionnaires after the 6-week treatment
period. These data have been published elsewhere (Van Dijk
et al., 2005). On the other hand, eﬀects on the rest-activity
rhythm may not show immediate measurable clinical eﬀects.
One might argue that long-term daily stimulation (e.g. during
several months or more) may induce eﬀects on the rest-activity
rhythm that are noticed by the partner or other caregivers in
the present study. Future investigations with longer treatment
periods and clinically relevant outcome measures – such
as number of participants admitted to a professional care
facility – may provide answers to this important question.
In conclusion, the results of the present study show near-
signiﬁcant eﬀects of electrical stimulation on the rest-activity
rhythm in AD. This partially lends support to the hypothesis
that neuronal stimulation enhances the rest-activity rhythm in
AD patients. The fact that treatment eﬀects were speciﬁcally
pronounced in those patients whowere not concomitantly using
AChEIs warrants further investigation. Future studies of non-
pharmacological interventions, including peripheral electrical
nerve stimulation, should take medication use into account.
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